Your session is about to expire
← Back to Search
Avelumab for Cancer
Study Summary
This trial will monitor the safety and tolerability of avelumab in cancer patients who continue treatment with avelumab.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 19 Patients • NCT03006848Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My treatment is associated with Merck Serono in Japan.I meet other specific requirements for the trial.I am currently enrolled in a clinical study sponsored by EMD Serono/Merck KGaA for avelumab treatment.I am allergic to one or more ingredients in the study treatment.I understand there may be other reasons I might not qualify for this trial.I am currently in an avelumab study and either receiving the treatment or in follow-up.The investigator thinks that you should not participate in the study for some other reason.
- Group 1: Avelumab
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does Avelumab have a high rate of adverse effects?
"Avelumab's safety is backed by both efficacy data from Phase 3 trials as well as multiple rounds of supporting safety data, so it received a score of 3."
Are there any vacancies in this trial for patients who want to participate?
"This clinical trial, as stated on the website clinicaltrials.gov, is not recruiting patients at this time. The first posting was on March 22nd, 2019 and the most recent update was October 4th, 2022. It is worth noting that there are 588 other trials enrolling patients as of right now."
What are some of the previous research projects that have included Avelumab?
"As of now, there are one hundred and sixteen clinical trials evaluating the efficacy of Avelumab. Out of these, ten have reached Phase 3. Most locations for these trials are in Barcelona and South dakota; however, there are three thousand six hundred and ninety-one sites worldwide where patients can enroll."
Is this a new or innovative clinical trial?
"Avelumab has been trialed in 116 separate studies conducted across 52 countries and 1024 cities. The first Avelumab clinical trial was sponsored by EMD Serono Research & Development Institute, Inc. in 2014. That study completed its Phase 2 drug approval stage that year after involving 204 patients. 47 more trials have occurred since then."
Are there any other research centers conducting this same trial in North America?
"Patients are currently being accepted at 28 different locations including Hematology - Oncology Associates of the Treasure Coast - Hematology-Oncology Associates of Treasure Coast in Port Saint Lucie, Florida, Michigan State University in Lansing, Michigan, and Maryland Oncology Hematology, P.A. in Rockville, Maryland."
How many individuals are being given this opportunity to participate in the clinical trial?
"No, this particular trial has completed patient recruitment. The listing for the study was first published on March 22nd, 2019 and edited for the last time on October 4th, 2022. There are currently 472 other trials involving solid tumors that are actively recruiting patients and 116 studies using Avelumab have open enrollment."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger